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Abstract: Hypertension affects populations globally and is thus a public health and  
socio-economic problem. Macronutrient and micronutrient deficiencies are common in the 
general population, and may be even more prevalent in hypertensive patients. This study 
aimed to determine a possible association between hypertension and intake of fat-soluble 
vitamins A, D and E. Participants were from the cross-sectional Hortega nutrition study 
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conducted with a random sample of 1514 people (50.3% women, 49.7% men) and two 
groups: nonhypertensive controls ≥40 years old (n = 429; 28.3%); unknown untreated 
hypertension cases ≥40 years old (n = 246; 16.2%). Biochemical and anthropometric 
measurements were taken. Data on dietary intakes, education, socio-economic status, place 
of residence, health habits, comorbidities, alcohol consumption and smoking were 
collected and assessed. A descriptive data study was done and compared by ANOVA and 
Chi-Square. No p value higher than 0.05 was considered significant. The results showed 
that vitamin A intake was higher in the hypertensive subpopulation (1732.77 ± 962.27 µg 
vs. 1655.89 ± 902.81 µg), and vitamin D and E intakes were lower (8.13 ± 9.71 µg vs.  
8.25 ± 9.52 µg and 18.79 ± 7.84 mg vs. 18.60 ± 8.20 mg, respectively). No statistically 
significant differences were found in any adjusted model. This study did not significantly 
associate intake of vitamins A, D and E with hypertension in people aged over 40. Future 
studies on this topic and a larger sample are necessary. 
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1. Introduction 
Arterial hypertension (AHT) has become a major public health problem in developed countries. 
Together with hypercholesterolemia and smoking, it represents a major cardiovascular risk factor, 
whose high prevalence and ability can be modified by therapeutic intervention and lifestyle changes. 
All these factors render it an extremely interesting public health and socio-economic issue [1], 
especially since some studies have indicated that by 2025, prevalence of AHT will affect 29% of all 
adults worldwide [2]. It has been assumed that good hypertension control could prevent many 
cardiovascular diseases, while lack of such control may consequently lead to a higher incidence of 
hospitalization and mortality from associated diseases, which together would mean higher health and 
social services costs. 
Hypertension is the result of a genetics-environmental interaction. Macronutrients and micronutrients 
are crucial for regulating blood pressure. The optimal combination of macronutrients and micronutrients 
has a significant impact on preventing and treating hypertension, in combination with drug therapy [3]. 
Early hypertension identification can help lower morbidity and mortality through cardiovascular 
disease (CD). The optimal age for hypertension screening is as of 40 years [4]. 
As the most cost-effective form, primary prevention can be accomplished mainly by reducing 
obesity, increasing physical activity, reducing alcohol intake to under 20–30 g per day, and eating a 
healthy low-salt diet, and sufficient potassium, fruits, vegetables, low-fat dairy products and minimum 
unsaturated fats [5]. A possible positive effect of antioxidant vitamins (E, C) has also been 
investigated, as reflected by different studies [6,7]. Failure in primary prevention results in society 
spending larger amounts on health. Even a modest reduction in AHT can have good public health 
benefits as it can help not only cut its incidence, but also control AHT subjects, and prevent major 
cardiovascular events and other associated diseases [8,9]. 
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Different works [10] reflect a drop in blood pressure (BP) levels with a vegetarian diet: here as 
responsible agents for a drop in BP we find a high fiber content, low-fat content or high mineral 
content, such as potassium and magnesium, and low salt, as well as a possible effect of antioxidant 
vitamins (E, C). 
Vitamins are a group of organic compounds that differ from one another in terms of their chemical 
composition, which the organism requires in small amounts to carry out specific metabolic functions 
within cells. Basically, we distinguish hydrosoluble vitamins and fat-soluble vitamins, such as vitamins 
A, D and E.  
Vitamin A and its analogs are important regulators of cell proliferation, differentiation and cell 
apoptosis, and are involved in immune functions. Retinoic acid is involved in embryonic kidney 
development by controlling branching morphogenesis [11,12]. Nonphysiological levels of vitamin A in 
pregnant women affect the organogenesis of newborns by lowering the number of nephrons in kidneys, 
which predisposes to future hypertension development in adulthood [5,11,13,14]. No studies have 
investigated the influence of vitamin A on hypertension development. Vitamin D deficiency can result 
from lack of exposure to ultraviolet B (UVB) radiation from the sun, which can lead to its limited 
production by the skin. One hypothesis states that if low levels of vitamin D can cause high BP, then 
supplementation of this vitamin might lower it as antihypertensive effects of vitamin D occur in 
patients with high BP and vitamin D deficiency; thus vitamin D supplementation may improve  
AHT [15–18]. Vitamin D hypovitaminosis is an independent risk factor of mortality in the general 
population. A meta-analysis published in 2013 showed that long-term vitamin D supplementation is 
associated with a significant reduction in mortality [19,20]. Vitamin D could also influence vascular 
biology by modulating endothelial function and inflammatory status [21]. All of this spells a 
significant issue because older adults are more susceptible to both vitamin D insufficiency and 
increased risk of CD [22]. Vitamin E (α-tocopherol) is a fat-soluble vitamin and one of the most 
important natural antioxidants [6] with several cardio-protective effects, such as reducing oxidative 
stress, increasing glucose utilization by insulin and improving the endothelial function of vessels [23]. 
A combination of antioxidant vitamins containing vitamin E, vitamin C, β-carotene, and zinc taken by 
hypertensive patients for 8 weeks has been described to lower BP and to increase nitric oxide 
metabolites in urine [24,25]. 
Finally as numerous studies have shown, nutrition plays a key role in health; specifically vitamins 
are essential and necessary micronutrients that are involved in numerous vital functions. In the 
literature, we have found independent studies on vitamins A,D and E, but none conducted together. 
These vitamins present anti-inflammatory and antioxidant effects, and their low serum concentration 
may be an important factor in early stages of the pathogenesis of many chronic diseases, such as 
hypertension [26,27]. We hypothesized that low levels of vitamins A, D and E are related to 
hypertension in adults. The objective of this study was to determine a possible association between 
hypertension and fat-soluble vitamins A, D and E intake in a cross-sectional study conducted in the 
city of Valladolid (Spain). 
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2. Materials and Methods 
2.1. Study Design  
We grounded our investigation on the results of the cross-sectional “Hortega Study” [28,29];  
a two-stage, nested, population-based, epidemiological case-control monitoring pilot study carried out 
in an adult population sample in the province of Valladolid (Spain). We randomly selected 20%  
(n = 35,901) of the population and stratified it according to hypertension and non-hypertension, and 
also to age and gender. People aged 90 years or more, nonresidents in the province, patients with clear 
cognitive impairment and terminal patients were excluded. This screening left a sample of 34,742 
people. Using uniform age- and sex-stratified random sampling, a representative subsample of the general 
population was selected (n = 1514). We used a broad battery of nutritional and health-related parameters. 
2.2. Study Population 
We started with a sample of 1514 people in a population aged 21–89 years; 50.3% were women and 
49.7% were men. BP was taken and, following the WHO criteria [30], the sample was divided into 
AHT (n = 654; 43.2%) and non-AHT (n = 860; 56.8%). In the AHT subpopulation, those patients not 
previously diagnosed with AHT were selected (n = 278; 18.4%). Finally, both subpopulations were 
selected from individuals aged over 40, which left a sample of 429 non-AHT individuals (controls) 
(28.3%) and 246 (16.2%) AHT patients (cases) (Figure 1). 
 
Figure 1. Flow diagram of the selection of study subpopulations. 
2.3. Patient Data 
 To carry out the study, information about age and gender was collected. Patients underwent a 
physical examination during which anthropometric variables BMI and waist/hip ratio and BP were 
measured (as recommended by the Joint National Committee [31] with an automatic HEM-711DLX 
IntelliSense, Automatic Blood Pressure Monitor, OMRON HEALTHCARE, China, validated and 
calibrated for this study). A blood sample was taken to determine different biochemical parameters 
(fasting glucose, triglycerides, HDL-cholesterol, LDL-cholesterol, total cholesterol) and existence of 
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comorbidities was assessed. Data on medications used (anti-hypertensive, anti-diabetics and anti-
hypolipidemics) were also collected. 
A nutritional survey consisting of three 24-hours recalls done on three different days and a  
semi-quantitative Food Frequency Questionnaire were conducted, while photographs of portions were 
collected to assess the intake of various dietary components. The average intake levels of various 
dietary components were also assessed by taking the average of the three 24-hours recalls and the 
semi-quantitative Food Frequency Questionnaire. The 24-hour recalls were transferred to the 
‘Alimentación y Salud’ (Diet and Health) program developed by the Institute of Nutrition and Food 
Technology, University of Granada [32] (Spain), which specified each food item eaten. This program 
then estimated the respective nutrients. We finally obtained the total energy and micronutrients intake 
specifically for vitamins A, D and E. 
2.4. Epidemiological Analysis 
 Categorical variables were expressed as percentages and continuous variables were reported as 
means (SD) for the normally distributed parameters, or as median and interquartile ranges. For the data 
analysis, a descriptive data study was performed with the IBM SPSS software (SPSS, version 17.0; 
SPSS Inc., Chicago, IL, USA). The mean values, and absolute and relative frequencies of the different 
variables were obtained in the two subpopulations and within each one after stratifying for gender. The 
data from the two subpopulations (total and gender) were compared by ANOVA (quantitative) and 
Chi-Square (qualitative). No p value higher than 0.05 was considered significant. In a second step, the 
analytical data study was performed by a logistic regression analysis to estimate a possible association 
between presence of AHT and intake of vitamins A, D or E. 
The variables of the intake of these fat-soluble vitamins were categorized according to whether they 
met the recommended daily intake (RDI) or were lower or higher than RDI. Individuals’ age and 
gender were taken into account (Table 1) and estimated using a logistic regression bivariate value and 
an unadjusted odds ratio (ORc) for all the intake categories of each vitamin compared to the  
reference category. 
Table 1. Recommended Daily Intake values of vitamins A, D and E for a Spanish 
population according to age and gender. 
Gender Age (years) Vitamin A (µg) Vitamin D (µg) Vitamin E (µg) 
Women 
40–49 800 5 8 
50–59 800 5 8 
60–69 800 10 8 
≥70 700 15 10 
Men 
40–49 1000 5 10 
50–59 1000 5 10 
60–69 1000 10 10 
≥70 900 15 12 
Notes: Taken from: Ortega et al.: Recommended daily intakes of energy and 
nutrients for the Spanish population. Madrid: Department of Nutrition. 
Universidad Complutense de Madrid; 2004 [33]. 
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A multivariate logistic regression analysis was done by designing a set of adjustment models with 
the different variables included, with which the adjusted odds ratio (ORa1, ORa2 and ORa3) were 
calculated for each fat-soluble vitamin and category (lower RDI or higher RDI).  
In a first step, age, gender and body mass index (BMI) were included with variables ‘age + gender + 
BMI’. ORa1: gender + age (every 10 years) + BMI (continuous). In a next step, comorbidities, such as 
presence or absence of diabetes mellitus (DM) and hypercholesterolemia, were included in the adjusted 
model. ORa2: gender + age (every 10 years) + BMI (continuous) + DM (yes/no) + hypercholesterolemia 
(yes/no). In a third step, the model was adjusted to fit the variables: smoking, alcohol consumption, 
exercise performed and energy intake. ORa3: gender + age (every 10 years) + BMI (continuous) + DM 
(yes/no) + hypercholesterolemia (yes/no) + smoking (smoker/ex-smoker/nonsmoker) + alcohol intake 
(0, >0 to 5, >5 to 15, >15 g of alcohol/day), exercise (METS total continuous) daily energy intake 
(kcal, continuous). 
3. Results  
3.1. General Characteristics and Anthropometrical Variables 
As shown in Table 2, the total hypertension prevalence of the study population aged over 40 years 
in this study was 43.2%, of whom 18.4% were newly diagnosed cases. In the 40–59 age group,  
non-hypertensive individuals (non-AHT: women 67.42%, men 61.45%; AHT: women 23.89%, men 
35.34%) predominated in both women and men. Moreover in those aged over 70 years, the percentage 
of AHT in men and women was much higher compared to non-AHT, with statistically significant 
differences in both cases (non-AHT: women 22.62%, men 28.37%; AHT: women 59.29%, men 
54.89%). However, this was not observed in the 60–69 year-old age group. 
Regarding weight and BMI, statistically significant higher values were obtained for women with 
AHT, and BMI values were 28.66 ± 4.99 and 25.36 ± 3.58, respectively. No statistically significant 
differences were observed for men between the values of these AHT and non-AHT variables. The only 
criteria followed were that the male population yielded a p-value under 0.05 for the waist/hip ratio 
when this value in men with AHT was higher than in non-AHT individuals. When attaching 
importance to these findings, both the BMI and waist/hip ratios become major factors, which can lead 
to obesity, a factor closely connected to hypertension. 
Among all the non-AHT individuals, one man and one woman on diuretic-type anti-hypertension 
treatment (prescribed for kidney pathology), and among the AHT subjects, only 4.4% of women and 
3.8% of men in both cases, were 80% IECAS and 20% diuretics. We also identified a greater 
requirement of antidiabetic and hypolipidemic medications among AHT subjects. However we found 
no statistically significant differences with non-AHT, nor for gender. 
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Table 2. General characteristics and anthropometric variables. 
Variable 
Non-AHT (n = 429; 63.6%) AHT (n = 246; 36.4%) 
Women  
(n = 221; 51.5%) 
Men  
(n = 208; 48.5%) 
Women  
(n = 113; 45.9%) 
Men  
(n = 133; 54.1%) 
N %/Mean ± SD N %/Mean ± SD N %/Mean ± SD N %/Mean ± SD 
Age 40–59 149 67.42 * 128 61.54 * 27 23.89 * 47 35.34 * 
 60–69 22 9.95 21 10.10 19 16.81 13 9.77 
 >70 50 22.62 * 59 28.37 * 67 59.29 * 73 54.89* 
Weight (kg)  62.21 ± 8.84 * 201 76.44 ± 10.78 111 66.82 ± 12.96 * 129 77.09 ± 12.01 
BMI  25.36 ± 3.58 * 208 26.75 ± 3.22 112 28.66 ± 4.99 * 133 27.38 ± 3.57 
Waist/hip  0.81 ± 0.09 206 0.94 ± 0.07 * 110 0.84 ± 0.10 130 0.96 ± 0.06 * 
Medication         
Anti-HTA         
No medication  99.5 207 99.5 108 95.6 128 96.2 
On medication  0.5 1 0.5 5 4.4 5 3.8 
IECAs  0 0 0 4 80 4 80 
Diuretics  100 1 100 1 20 1 20 
Anti-DM         
No medication  99.1 199 95.7 103 91.2 126 94.7 
On medication  0.9 9 0.3 10 8.8 7 5.3 
Oral antidiabetics  50 4 44.4 4 40 3 42.9 
Insulin  50 5 55.6 6 60 4 57.1 
Anti-hypolipidemics         
No medication  97.3 196 94.2 104 92.0 123 92.5 
On medication  2.7 12 5.8 9 8.0 10 7.5 
Notes: * p-value ≤ 0.05 (Chi-square; ANOVA test); AHT: Arterial hypertension; SD: Standard Deviation; 
BMI: Body Mass Index. 
3.2. Blood Pressure, Biochemical Parameters and Vitamins Intake 
In Table 3, we observe the BP and biochemical parameters: the mean SBP and DBP were generally 
lower in non-AHT (women SBP: 118.64 ± 12.11 mmHg; DBP: 75.70 ± 7.66 mmHg and men SBP: 
123.51 ± 10.44 mmHg; DBP: 76.41 ± 6.86 mmHg) than in AHT (women SBP: 152.00 ± 15.42 mmHg; 
DBP: 87.30 ± 9.40 mmHg and men SBP: 150.61 ± 15.90 mmHg; DBP: 87.13 ± 10.05 mmHg). In all 
cases, statistically significant differences were obtained.  
For the mean triglycerides values, significant differences for both women and men were observed, 
with higher mean values found in the AHT subpopulation (women: 165.64 ± 85.30 mg/dL; men: 
228.25 ± 152.83 mg/dL) compared to the non-AHT subpopulations (women 142.04 ± 67.31 mg/dL; 
men: 212.02 ± 107.89 mg/dL). We observed no statistically differences between AHT and non-AHT in 
relation to total energy intake. 
For the mean values of fasting glucose, that is, in men with AHT (98.62 ± 24.94 mg/dL) and 
women with AHT (94.03 ± 14.40 mg/dL), we observed statistically significant differences compared 
to their corresponding subpopulations of non-AHT individuals (men 92.30 ± 18.33 mg/dL; women 
88.77 ± 12.17 mg/dL). Prevalences of DM, kidney damage, metabolic syndrome and hyper-triglyceridemia 
were higher in the AHT patient group (for men and women) (p < 0.05). 
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Table 3. Blood pressure, biochemical parameters, vitamins intake and prevalence of comorbidities. 
Variable 
Non-AHT (n = 429; 63.6%) AHT (n = 246; 36.4%) 
Women (n = 221; 51.5%) Men (n = 208; 48.5%) Women (n = 113; 45.9%) Men (n = 133; 54.1%) 
N %/Mean ± SD N %/Mean ± SD N %/Mean ± SD N %/Mean ± SD 
Systolic blood pressure (mmHg) 218 118.64 ± 12.11 * 207 123.51 ± 10.44 * 112 152.00 ± 15.42 * 132 150.61 ± 15.90 * 
Diastolic blood pressure (mmHg) 218 75.70 ± 7.66 * 207 76.41 ± 6.86 * 112 87.30 ± 9.40 * 132 87.13 ± 10.05 * 
Triglycerides (mg/dL) 221 142.04 ± 67.31 * 208 212.02 ± 107.89 113 165.64 ± 85.30 * 133 228.25 ± 152.83 
HDL cholesterol (mg/dL) 221 59.11 ± 13.58 208 45.79 ± 11.88 113 56.25 ± 14.48 133 47.64 ± 12.24 
LDL cholesterol (mg/dL) 221 122.94 ± 32.58 208 121.79 ± 33.06 113 128.98 ± 33.79 133 117.68 ± 35.03 
Total cholesterol (mg/dL) 221 210.47 ± 37.35 208 209.98 ± 34.66 113 218.36 ± 36.01 133 210.97 ± 41.73 
Fasting glucose (mg/dL) 221 88.77 ± 12.17 * 208 92.30 ± 18.3 3* 113 94.03 ± 14.40 * 133 98.62 ± 24.94 * 
Diabetes mellitus 3 1.4 * 11 5.3 * 10 8.8 * 15 11.3 * 
Kidney damage 5 2.3 * 4 1.9 * 10 9.0 * 13 9.8 * 
Metabolic syndrome 25 11.3 * 41 19.7 * 40 35.4 * 53 39.8 * 
Hypertriglyceridemia 108 50.5 108 55.1 51 49.0 58 47.2 
Hypercholesterolemia 29 13.2 * 38 18.3 27 23.9 * 22 16.5 
Obesity 35 17.0 * 49 24.3 46 41.4 * 35 26.7 
Overweight 102 49.5 * 151 74.8 85 76.6 * 99 75.6 
Total energy (kcal/day) 221 4311.22 ± 1546.59 208 4566.67 ± 1623.22 113 4650.59 ± 1470.62 133 4564.06 ± 1680.60 
VITAMINS: Vit. A (µg/day) 221 1650.03 ± 908.85 * 208 1661.76 ± 899.54 113 1977.00 ± 1016.82 * 133 1533.96 ± 870.43 
Vit. D (µg/day) 221 7.70 ± 9.76 208 8.68 ± 9.29 113 7.96 ± 9.93 133 8.27 ± 9.57 
Vit. E (µg/day) 221 17.91 ± 8.22 208 19.27 ± 8.30 113 18.44 ± 7.48 133 19.12 ± 8.19 
Notes: * p-value ≤ 0.05 (Chi-square; ANOVA test); AHT: Arterial hypertension; HDL: High Density Lipoproteins; LDL: Low Density Lipoproteins. 
Table 4. Comorbidities and vitamin intake. 
Variable 
Non-AHT (n = 429; 63.6%) AHT (n = 246; 36.4%) 
  Vitamin A  Vitamin D  Vitamin E   Vitamin A Vitamin D Vitamin E  
N Mean (µg) ± SD Mean (µg) ± SD Mean (mg) ± SD N Mean (µg) ± SD Mean (µg) ± SD Mean (mg) ± SD 
Diabetes mellitus 14 2688.55 ± 2065.74 * 16.61 ± 50.11 19.73 ± 9.25 35 1808.94 ± 820.34 * 32.64 ± 64.98 21.80 ± 7.47 
Kidney damage 9 868.85 ± 797.70 3.45 ± 3.61 10.11 ± 7.04 * 23 2830.17 ± 5826.18 8.47 ± 12.12 17.56 ± 8.68 * 
Metabolic syndrome  66 2617.44 ± 4422.13 12.39 ± 29.83 19.40 ± 10.15 93 2100.90 ± 3068.78 13.14 ± 44.83 18.72 ± 12.86 
Hypertriglyceridemia 216 2327.85 ± 3792.64 11.20 ± 27.83 18.95 ± 10.61 109 2149.84 ± 2876.60 18.01 ± 52.52 19.62 ± 12.32 
Hypercholesterolemia 67 2170.14 ± 2712.68 10.027 ± 14.22 18.58 ± 11.14 49 2712.68 ± 3997.04 15.67 ± 40.59 20.41 ± 12.22 
Obesity 84 1609.50 ± 2051.38 7.09 ± 10.80 * 16.66 ± 8.34 81 2260.91 ± 3711.34 16.24 ± 40.14 * 18.17 ± 9.39 
Overweight 253 2200.86 ± 3547.93 11.64 ± 26.03 19.33 ± 10.78 184 2003.96 ± 2575.37 13.74 ± 31.56 18.35 ± 9.91 
Notes: * p-value ≤ 0.05 (Chi-square; ANOVA test); AHT: Arterial hypertension; SD: Standard Deviation. 
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No statistically significant differences were observed between the mean values of total cholesterol, 
high density lipoproteins (HDL) and low density lipoproteins (LDL) cholesterol between the AHT and 
non-AHT populations for both genders. 
Regarding daily vitamin intake, differences were observed for vitamin A between the two female 
subpopulations, and the average value was higher in the AHT population (AHT 1977.00 ± 1016.82 mg; 
non-AHT 1650.03 ± 908.85 mg). In all the other cases, no p-values under 0.05 were obtained. 
Based on the results in Table 4, we can state that the non-AHT patients diagnosed with DM 
reported a significantly higher intake of vitamin A compared to AHT (2688.55 ± 2065.74 µg vs. 
1808.94 ± 820.34 µg). This suggests that higher vitamin A intake might have protective effects. In the 
group of patients with kidney damage, vitamin E intake levels were higher among AHT patients than 
among non-AHT ones. We found no differences in intake of vitamin A, D and E in the groups of 
patients with metabolic syndrome, hypertriglyceridemia and hypercholesterolemia, nor between AHT 
and non-AHT patients. However, patients with obesity and AHT presented high levels of vitamin D intake. 
For kidney damage, intake of the studied vitamins was generally higher in the AHT subpopulation, 
with statistically significant differences for vitamin E (10.11 ± 7.04 mg vs. 17.56 ± 8.68 mg). Finally 
for obesity cases, vitamin E intake was significantly higher in the AHT subpopulation (16.24 ± 40.14 µg 
vs. 7.09 ± 0.80 µg). In all the other cases, no statistically significant differences were found. 
3.3. Prevalence of Comorbidities 
Table 3 also provides the results of prevalence of comorbidities; in the female population, 
prevalence was generally higher in the AHT subpopulation compared to non-AHT: DM (8.8% AHT 
vs. 1.4% non-AHT), kidney damage (9.0% AHT vs. 2.3% non-AHT), metabolic syndrome (35.4% 
AHT vs. 11.3% non-AHT), hypercholesterolemia (23.9% AHT vs. 13.2% non-AHT), obesity (41.4% 
AHT vs. 17.0% non-AHT) and overweight (76.6% AHT vs. 49.5% non-AHT), and with statistically 
significant differences.  
In the male subpopulation, statistically significant differences were obtained when comparing 
prevalence of DM (11.3% AHT vs. 8.8% non-AHT), kidney damage (9.8% AHT vs. 1.9% non-AHT) 
and metabolic syndrome (39.8% AHT vs. 19.7% non-AHT), and these were higher in the subpopulation 
of hypertensive men.   
 No significant differences were found neither between sexes nor between the AHT and non-AHT 
subpopulations for hypertriglyceridemia (women 49.0% AHT vs. 50.5% non-AHT; men 47.2% AHT 
vs. 55.1% non-AHT) and hypercholesterolemia (women 23.9% AHT vs. 13.2% non-AHT; men 16.5% 
AHT vs. 18.3% non-AHT). 
The results obtained for the obesity and overweight measurements were interesting, as confirmed by 
factors in hypertension development, where significant differences were obtained for women (obesity 
41.4% AHT vs. 17.0% non-AHT; overweight 76.6% AHT vs. 49.5% non-AHT), but not for men 
(obesity 26.7% AHT vs. 24.3% non-AHT; overweight: 75.6% AHT vs. 74.8% non-AHT). 
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3.4. Multivariate Analysis 
Table 5 shows the results of the logistic regression analysis. In no ORc cases were statistically 
significant differences found in the values obtained, except for the ‘lower RDI’ vitamin D value, with a 
value of 0.47 (95%CI: 0.24–0.93). This suggests that daily intake below the RDI is negatively 
associated with presence of hypertension. 
Table 5. Analysis of the bivariate and multivariate logistic regressions. 
Variable RDI Lower RDI Higher RDI 
Vitamin A 
Non-AHT (n (%)) 36 (60.0) 34 (63.0) 250 (60.8) 
AHT (n (%)) 24 (40.0) 20 (37.0) 161 (39.2) 
ORc (95%CI) 1.00 (ref) 0.97 (0.57–1.68) 0.88 (0.41–1.88) 
ORa1 (95%CI) 1.00 (ref) 1.08 (0.59–1.99) 0.91 (0.40–2.07) 
ORa2 (95%CI) 1.00 (ref) 1.17 (0.63–2.15) 1.80 (0.86–3.74) 
ORa3 (95%CI) 1.00 (ref) 1.29 (0.65–2.54) 1.55 (0.73–3.31) 
Vitamin D 
Non-AHT (n (%)) 23 (53.5) 180 (57.9) 118 (71.1) 
AHT (n (%)) 20 (46.5) 131 (42.1) 48 (28.9) 
ORc (95%CI) 1.00 (ref) 0.47 (0.24–0.93) * 0.84 (0.44–1.59) 
ORa1 (95%CI) 1.00 (ref) 1.77 (0.83–3.80) 1.71 (0.83–3.52) 
ORa2 (95%CI) 1.00 (ref) 1.85 (0.85–4.01) 1.80 (0.86–3.74) 
ORa3 (95%CI) 1.00 (ref) 1.91 (0.86–4.24) 1.55 (0.73–3.31) 
Vitamin E 
Non-AHT (n (%)) 19 (65.5) 17 (60.7) 240 (66.3) 
AHT (n (%)) 10 (34.5) 11 (39.3) 122 (33.7) 
ORc (95%CI) 1.00 (ref) 0.97 (0.44–2.14) 1.23 (0.42–3.61) 
ORa1 (95%CI) 1.00 (ref) 0.90 (0.36–2.25) 0.70 (0.20–2.39) 
ORa2 (95%CI) 1.00 (ref) 0.91 (0.36–2.26) 0.73 (0.21–2.52) 
ORa3 (95%CI) 1.00 (ref) 1.04 (0.38–2.85) 0.78 (0.22–2.76) 
Notes: * p-value ≤ 0.05 (Chi-square); RDI: Recommended Daily Intake; AHT: Arterial Hypertension; 
CI: Confidence Interval; ORa1: gender + age + BMI; ORa2: gender + age + BMI+ DM + 
hypercholesterolemia; ORa3: gender + age + BMI + DM + hypercholesterolemia + smoking + alcohol 
consumption + exercise + daily energy intake. 
The ORa1 values obtained for vitamin A were similar to those of ORc. Regarding vitamin D, we 
noted that after including and adjusting variables, the trend obtained in the bivariate analysis reversed, 
with ORa1 above 1. However, we found no statistically significant CIs. Finally for vitamin E, we 
observed a change in the ‘higher RDI’ category, less than 1, but no statistically significant ORa1. 
In all the ORa values, no statistically significant confidence intervals were obtained, which were 
stable for both vitamins D and E. For vitamin A, the ORa2 value was higher compared to the 
corresponding ORa1, especially in the ‘higher RDI’ category. P values were never under 0.05. 
In all cases a trend was seen for the adjusted and crude models, except for the ‘lower RDI’ vitamin 
E category, where the ORa3 value was higher than 1, but the confidence interval included unit 1. 
Therefore based on these results, the possible association between the daily intake levels of these 
vitamins and presence of hypertension was not likely in our study population. 
  




In a community-based population with older subjects (aged over 40 years), we found a hypertension 
prevalence of 43.2%, of whom 16.2% had been recently diagnosed. For age, we observed more 
hypertensive individuals (men and women) in the group aged over 70 years, and AHT was associated 
with increased weight and BMI in women, and with a higher waist/hip ratio in men. Regarding the 
biochemical parameters, AHT was associated with an increased level of triglycerides and fasting 
glucose. In relation to comorbidities in AHT patients, although they were recently diagnosed cases, 
they were associated with increased DM, kidney damage and metabolic syndrome for both genders, 
and with hypercholesterolemia, obesity and overweight in women. We did not observe differences in 
vitamin D and E between AHT and non-AHT, but vitamin A was high in the AHT group (both men 
and women). This is possibly because the strategy to prevent hypertension is at the forefront to 
improve eating habits, which supports the low prescription frequency of anti-hypertensive treatments 
that we observed among hypertension patients. Despite there being newly diagnosed AHT cases, the 
increased presence of comorbidities in this group is particularly relevant. 
For our epidemiological study, we opted for a case-control design which allowed us to assess or 
estimate the positive or negative association between various parameters, this being the objective of 
our study, and development of hypertension by calculating odds ratio (ORs). The selection criterion 
was BP, thus significant differences were found between groups for both the total sample and its 
distribution according to gender and age.  
From the results obtained herein, we were unable to identify an association between fat-soluble 
vitamins A, D, E intake and AHT. However, we started with a discrepancy in the results observed in 
the literature review, clinical trials and studies done in experimental animals, which supports the 
involvement of vitamins E and C in lowering AHT or helping drug treatments thanks to their high 
antioxidant effect by acting synergistically on oxidative stress in AHT. Despite there being newly 
diagnosed cases of AHT, we were struck by the increased presence of comorbidities among them.  
We must also emphasize that we assessed vitamin intake, and one weakness of our study was that 
serum levels of these vitamins was lacking, so absorption may have been impaired. 
As we hypothesized an association between AHT and intake of fat-soluble vitamins A, D and E, we 
decided to control the confounding factors that might have distorted the results. This is why we took 
into account anthropometric measurements, biochemical determinations, pathophysiological and other 
factors to help establish and assess the extent of this association. 
The majority of the control subpopulation (non-AHT) fell into the 49–59 age group, while 
individuals aged over 70 years predominated in the hypertensive subpopulation. In this study we saw 
how the number of nondiagnosed cases of hypertension in the study population was 18.4%. This figure 
is high and must be taken into account given the importance of knowledge of hypertension and control 
in cardiovascular failure risk prevention. These results agree with those reported in the literature on BP 
rising with age (>60% over 60 years), particularly in hypertensive individuals. 
The results of the anthropometric measurements revealed that the AHT subpopulation had higher 
BMI, weight and waist/hip ratios, of which the last meaasurement was more pronounced among AHT 
women. The positive association between body weight and BP has been also confirmed by the results 
obtained in the Intersalt study [34]. 
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Continuous growth in obesity in the general population, along with a larger number of associated 
diseases such as DM, dyslipidemia or cardiovascular diseases, have established a direct relationship 
with increased AHT prevalence in society today. Therefore biochemical measurements were taken. 
From the results we should note that the mean values of triglycerides and fasting glucose were higher 
in the AHT subpopulation, and that AHT was a predictive variable of cardiovascular risk (according to 
the Spanish Society of Cardiology). We found no statistically significant differences between mean 
cholesterol values and our subpopulations, although both values were higher than recommended by the 
Spanish Society of Cardiology—200 mg/dL. 
The comorbidity data collected from our population showed that AHT is associated with kidney 
damage, DM, metabolic syndrome, obesity and being overweight, with a higher prevalence in the AHT 
subpopulation and statistically significant differences. These findings coincide with conclusions drawn 
from other AHT prevalence studies conducted in different locations. 
For macronutrients intake, whose values were obtained by averaging the data from the 24-hour 
recalls and the semi-quantitative Food Frequency Questionnaire, the results clearly show intake of 
proteins, carbohydrates and fats, which was higher in the AHT subpopulation than in the nonAHT 
subpopulation. Nonetheless the differences between them were not statistically significant, so we were 
unable to associate the higher intake of these nutrients with hypertension. Intake of vitamin A was 
significantly higher in non-AHT diabetic patients, as were vitamin E in AHT patients with kidney 
damage and vitamin D intake in obese AHT patients. Although these findings might suggest a 
correlation, further research needs to be conducted to confirm this association.  
One of the limitations of this study was our assessment of nutrients and accuracy of the food intake 
data since no accurate method has yet been developed. In order to limit them in our study, we used 
records for three different days, and validated questionnaires and photographs to determine portion 
sizes. Furthermore, the averages of two different methods and validated software to transform food 
intake into nutrients and to calculate mean values were used. Another significant limitation of this 
study is that it lacks biomarker micronutrients (vitamins A,D and E) in serum. 
The literature available on vitamin A and AHT has studied the importance of vitamin A on the 
genesis of AHT as this vitamin is involved in embryonic kidney development; therefore when 
deficient, the final number of nephrons may be manifested in adulthood as AHT [5,11,35,36]. 
However, we found no study that has been conducted on the influence of excess or deficient vitamin A 
intake in an adult AHT population. From the data obtained in our study population, we conclude that 
we cannot claim this association as we observed no statistically significant difference in vitamin intake 
between the two study subpopulations. 
The results of studies and literature reviews on vitamin D mention an association between hypertension 
and vitamin D, and refer to a deficiency of this vitamin in individuals with AHT [17,18,37,38].  
In these studies, we noted that the study population reported a deficient vitamin D intake, and that such 
supplementation could improve these individuals’ antihypertensive status. Yet other studies [39] have 
found no significant effect of vitamin D supplementation. No negative association has been observed 
between vitamin D and hypertension in individuals in whom the plasma concentrations of this vitamin 
gave normal values (40.00–80.00 ng/mL) [12]. Although we initially observed a significant ORc 
difference in our study for the ‘lower RDI’ category, which could mean a negative association between 
vitamin D and AHT, it was not relevant for ORa. Therefore, no significant association was found in 
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either subset. According to the adjusted RDI mean values, vitamin D intake in both subpopulations 
was practically the same in both cases. So we assume that there was no association and it should, 
accordingly, not affect BP. 
Studies on vitamin E and AHT [40] have been conducted to associate the antioxidant effect of this 
vitamin on oxidative stress in AHT. However, this effect is achieved with high levels of vitamin E 
(higher than 400 IU/day), which may prove toxic. Other studies have shown [41] that obesity in 
adolescents is associated with high levels of LDL and low plasma α-tocopherol content. Thus a 
combination of vitamin C and E has been used in most studies This combination exerts a hypotensive 
effect, even with a smaller amount of vitamin E, due to the synergy between them. In our population, 
we observed that our values fell within the recommended limits in both subpopulations, and we noted 
no statistically significant differences between subpopulations, which suggests no positive or negative 
association between vitamin E intake and AHT. If there was an association, it may possibly not have 
been observed because the intake levels of our population were not high enough to enable vitamin E to 
execute its antioxidant properties to lower BP. 
Hypertension as a global problem needs to be effectively treated. The most effective way, and also 
by far the cheapest, is prevention to lower prevalence levels, and beginning by covering primary 
prevention from early ages, e.g., children and adolescents, is advised [42]. Investments in educating 
populations about healthy habits and proper nutrition, led by a Mediterranean diet, further promotion 
of the importance of daily physical activity, and reducing salt intake will be paid back by lowering the 
cost of treatment of developed hypertension and associated diseases. 
5. Conclusions 
This population-based study conducted in Spain indicates the importance of hypertension in 
populations aged over 40 years, specifically for intakes beyond the recommended levels of fat-soluble 
vitamins A and D, which has been identified to possibly increase the risk of hypertension, but not 
statistically significantly. However, this association has not been identified for vitamin E after 
adjusting for gender, age, BMI, diabetes mellitus, hypercholesterolemia, smoking, alcohol, exercise 
and daily energy intake. In this context, our results have not significantly associated the intake of 
vitamins A, D and E with hypertension in people aged over 40 years. Therefore, future studies on this 
topic and a larger sample are needed. 
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